Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for Antibody-Drug Conjugates (ADCs). Mc-Val-Cit-PABC-PNP acts as a substrate for lysosomal proteases (such as cathepsin B) via its valine-citrulline dipeptide sequence. Upon enzymatic cleavage in the tumor microenvironment, Mc-Val-Cit-PABC-PNP releases the drug payload, while enabling precise drug release control through a self-immolative spacer. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates and related cancer therapy research[1-4].
References:
[1] Bisbal Lopez L, Ravazza D, Bocci M, et al. Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker. Front Pharmacol. 2023 Dec 6;14:1320524.
[2] Che-Leung Law, Julie McEarchern, Jonathan Drachman. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders. Patent WO2005081711A2.
[3] James P. Basilion, Xinning Wang, Natalie Walker. Psma targeted conjugate compounds and uses thereof. Patent. US20250222122A1.
[4] Fumiyoshi Okano, Takanori Saito. Conjugate of caprin-1 antibody linked to immune activator for cancer treatment. Patent. US20250249092A1.
Mc-Val-Cit-PABC-PNP是一种组织蛋白酶可裂解的抗体偶联药物(ADC)肽连接子。Mc-Val-Cit-PABC-PNP通过其缬氨酸-瓜氨酸二肽序列作为溶酶体蛋白酶(如组织蛋白酶B)的底物,在肿瘤微环境中被酶切后释放药物有效载荷,同时通过自消除间隔基实现精确的药物释放控制。Mc-Val-Cit-PABC-PNP可用于抗体偶联药物的合成及相关癌症治疗研究[1-4]。
















